Clinical Trial Update: Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia

View source ↗

Summary

The study reports that consistent use of 5-alpha reductase inhibitors in benign prostatic hyperplasia is associated with clinical benefits. It also demonstrates…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• DUTASTERIDE (Dutasteride)
• FINASTERIDE (FINASTERIDE)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Prostatic Hyperplasia | Status: COMPLETED | Results posted: 2011-11-28